Dr. Sharma on the Rationale to Combine Veliparib With Chemotherapy in TNBC


Priyanka Sharma, MD, discusses the rationale to combine veliparib with chemotherapy in triple-negative breast cancer.

Priyanka Sharma, MD, professor of medicine, University of Kansas Medical Center, discusses the rationale to combine veliparib (ABT-888) with chemotherapy in triple-negative breast cancer (TNBC).

During the 2020 ASCO Virtual Scientific Program, findings from the randomized phase 2 SWOG S1416 trial demonstrated improved progression-free survival with the addition of veliparib to cisplatin in patients with BRCA-like TNBC compared with cisplatin alone.

About half of patients with TNBC that do not carry germline BRCA1/2 mutations are homologous recombination deficient (HRD), Sharma says. In the phase 2 study, HRD-positive patients are categorized as having a BRCA1-like phenotype.

Additionally, PARP inhibitors have demonstrated efficacy in patients with BRCA-mutant metastatic breast cancer in ovarian cancer and prostate cancer, explains Sharma. However, PARP inhibitors have not demonstrated efficacy in patients who do not have BRCA-mutant breast cancer.

As such, the study aimed to evaluate the potential role of PARP inhibitors in a select patient population beyond patients with BRCA-positive disease, Sharma concludes.

Related Videos
Arpita Desai, MD
Qian (Janie) Qin, MD
Melissa L. Johnson, MD
Adrienne Phillips, MD, MPH
Jeffrey S. Weber, MD, PhD
In this fourth episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, discuss how to appropriately manage patients with stage IV breast cancer and outline when surgical approaches may be appropriate for this population.
Hope Rugo, MD, an expert on breast cancer, presenting slides
Manojkumar Bupathi, MD, MS
Mylin A. Torres, MD
Bernd Kasper, MD, PhD